Meag Munich Ergo Kapitalanlagegesellschaft MBH lessened its stake in Johnson & Johnson (NYSE:JNJ) by 92.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 12,422 shares of the company’s stock after selling 146,656 shares during the quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Johnson & Johnson were worth $1,587,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. HC Financial Advisors Inc. boosted its position in Johnson & Johnson by 7.2% during the 3rd quarter. HC Financial Advisors Inc. now owns 15,776 shares of the company’s stock valued at $2,180,000 after acquiring an additional 1,060 shares in the last quarter. Spinnaker Trust boosted its position in Johnson & Johnson by 4.0% during the 3rd quarter. Spinnaker Trust now owns 82,095 shares of the company’s stock valued at $11,342,000 after acquiring an additional 3,188 shares in the last quarter. M. Kraus & Co boosted its position in shares of Johnson & Johnson by 0.9% in the 3rd quarter. M. Kraus & Co now owns 44,402 shares of the company’s stock worth $6,135,000 after purchasing an additional 405 shares in the last quarter. Schmidt P J Investment Management Inc. boosted its position in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Schmidt P J Investment Management Inc. now owns 59,088 shares of the company’s stock worth $8,164,000 after purchasing an additional 395 shares in the last quarter. Finally, Telemus Capital LLC boosted its position in shares of Johnson & Johnson by 2.6% in the 3rd quarter. Telemus Capital LLC now owns 33,191 shares of the company’s stock worth $4,586,000 after purchasing an additional 845 shares in the last quarter. Institutional investors and hedge funds own 70.80% of the company’s stock.
A number of brokerages have recently commented on JNJ. Raymond James boosted their price target on Johnson & Johnson from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Credit Suisse Group boosted their price target on Johnson & Johnson from $152.00 to $156.00 and gave the stock an “outperform” rating in a research report on Thursday, May 16th. Wells Fargo & Co reissued an “outperform” rating and issued a $157.00 price target (up from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target on the stock in a research report on Wednesday, March 27th. Finally, Barclays reissued an “equal weight” rating and issued a $135.00 price target (down from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $147.30.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The firm had revenue of $20.02 billion for the quarter, compared to analysts’ expectations of $19.55 billion. During the same period in the previous year, the firm posted $2.06 EPS. The business’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th will be issued a $0.95 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date of this dividend is Friday, May 24th. Johnson & Johnson’s payout ratio is presently 44.01%.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Sold by Meag Munich Ergo Kapitalanlagegesellschaft MBH” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4350124/johnson-johnson-jnj-shares-sold-by-meag-munich-ergo-kapitalanlagegesellschaft-mbh.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is included in the gross domestic product?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.